Develops AAV-based gene therapies for rare genetic diseases; co-developed Hemgenix, the first approved hemophilia B gene therapy.
Develops AAV-based gene therapies for rare genetic diseases; co-developed Hemgenix, the first approved hemophilia B gene therapy.
Hemgenix, the hemophilia B gene therapy, is sold by CSL Behring, so uniQure's own income from it comes as milestone and royalty payments rather than product sales. With nothing else on the market, it finances its main programme, a one-time gene therapy delivered into the brain for Huntington's disease, with those payments and share sales.
Moat: narrow (IP / patents, process know-how). Pioneer in AAV gene therapy manufacturing with an approved product and a royalty stream from CSL Behring.
Headquarters: Amsterdam, Netherlands · Founded: 1998 · Employees: 221
Size uniQure (QURE) is a United States Health Care company (Biotechnology) with a market value of $1.42B, the 2001st largest of 3,085 United States companies the cockpit tracks. Shares closed at $20.30 on 18 Nov 2026.
Performance Over six months the shares fell 17.5%, against -20.3% for the median peer and -2.2% for the United States market (cap-weighted) — 10th highest of 20 in its peer set.
Growth Revenue grew 28.0% over the last twelve months (peer median +20.3%); the operating margin is -1,026.9% (peer median -61.2%).
Valuation It trades at 65.4× enterprise value to sales against a peer median of 17.2× (6th most expensive of 17).
Capital Return on invested capital runs 95.1 points below its cost of capital (9.3% WACC).
Short interest Short interest is 12.1% of the free float (30 Oct 2026).
Next results Next results expected around 1 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $20.2M | $16.1M | $27.1M | $15.8M | $106M |
| Revenue growth | — | -41% | +71% | -85% | — |
| Gross profit | $2.64M | -$347,000 | -$3.85M | -$9.69M | $94.6M |
| EBITDA | -$191M | -$171M | -$172M | -$259M | -$134M |
| Net income | -$233M | -$199M | -$240M | -$308M | -$127M |
| Free cash flow | -$193M | -$178M | -$186M | -$153M | -$163M |
| Capital expenditure | $735,373 | $439,000 | $11.7M | $7.15M | $17.7M |
| Total debt | $564M | $537M | $501M | $533M | $143M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| uniQure QURE | $1.42B | -17% | +28% | -1,027% | 65.4× | n/a |
| Sarepta Therapeutics SRPT | $1.56B | -15% | -19% | 0% | 0.9× | -6.8% |
| BioMarin Pharmaceutical BMRN | $11.9B | +22% | +20% | 19% | 4.2× | 8.2% |
| PTC Therapeutics PTCT | $5.03B | -15% | -35% | 22% | 3.1× | 6.6% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | QURE | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -10.6% | -12.3% | 11th highest of 21 |
| 6-month return | -17.5% | -20.3% | 10th highest of 20 |
| Distance from 52-week high | -60.8% | -45.9% | 4th lowest of 21 |
| Revenue growth (TTM) | +28.0% | +20.3% | 8th highest of 17 |
| Operating margin | -1,026.9% | -61.2% | 3rd lowest of 18 |
| EV / Sales | 65.4× | 17.2× | 6th most expensive of 17 |
| ROIC minus cost of capital | -95.1 pp | -15.4 pp | 3rd lowest of 10 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| uniQure QURE | United States | $1.42B | -17% | +28% | -1,027% | 65.4× | n/a | n/a |
| Nanjing Vazyme Biotech 688105.SS | China | $1.42B | +25% | +16% | -5% | 4.9× | 39.4% | -2.5% |
| Absci ABSI | United States | $1.41B | +65% | -47% | -9,155% | 835.7× | n/a | n/a |
| Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh IMCR | United States | $1.44B | -7% | +13% | -7% | 2.3× | n/a | n/a |
| AnaptysBio ANAB | United States | $1.40B | -22% | +13% | 62% | 7.9× | 0.5% | +25.6% |
| Wuhan Healthgen Biotechnology 688765.SS | China | $1.46B | -51% | +90% | -297% | 205.0× | n/a | n/a |
| UroGen Pharma URGN | United States | $1.46B | -1% | +159% | -12% | 6.3× | n/a | n/a |
| Rapport Therapeutics RAPP | United States | $1.39B | -34% | n/a | -838% | 50.1× | n/a | n/a |
| Fujian Haixi Pharmaceuticals 2637.HK | Hong Kong | $1.47B | -32% | +25% | 33% | n/a | n/a | n/a |
| CanSino Biologics 688185.SS | China | $1.38B | 0% | +30% | -4% | 6.6× | n/a | n/a |
| Oncolys BioPharma 4588.T | Japan | $1.37B | +181% | +1,749% | -295% | 408.9× | n/a | n/a |
| Intellia Therapeutics NTLA | United States | $1.37B | -20% | -8% | -821% | 21.3× | n/a | n/a |
| Mesoblast MSB.AX | Australia | $1.49B | -17% | +556% | -43% | 12.8× | n/a | n/a |
| Peptron 087010.KS | South Korea | $1.49B | -68% | -13% | -488% | 359.6× | n/a | n/a |
| Tyra Bioscience TYRA | United States | $1.35B | -41% | n/a | n/a | n/a | n/a | n/a |
| TLC BioSciences 7924.TWO | Taiwan | $1.50B | n/a | n/a | n/a | n/a | n/a | n/a |
| Chengdu Olymvax Biopharmaceuticals 688319.SS | China | $1.51B | -37% | +12% | 8% | 13.1× | n/a | n/a |
| Generate Biomedicines GENB | United States | $1.34B | -20% | +56% | -737% | 31.7× | n/a | n/a |
| Nuvation Bio NUVB | United States | $1.34B | -16% | +654% | -61% | 5.7× | n/a | n/a |
| Korsana Biosciences KRSA | United States | $1.52B | +54% | -64% | -5,277% | 1,058.7× | n/a | n/a |
| Kailera Therapeutics KLRA | United States | $1.53B | -41% | n/a | n/a | n/a | n/a | n/a |